Halozyme Therapeutics Inc.
HALO
NGS
Sector: Healthcare
Industry: Biotechnology
45.13
USD
-0.26
(-0.57%)
Optionable: Yes Market Cap: 6,612 M 90-day average vol: 0
Previous close: 45.39 Open: 45.0 Bid: 45.42 Ask: 45.42
52 week range
0.00 0.00
Last updated: Monday 8th August 2022
Get Access to 1 Billion Usable Market data points IN YOUR EXCEL SHEETS WITH EASY TO USE EXCEL FUNCTIONS
Get started todaySearch for a stock
Are you?
Metrics
Valuation
Price per Sales TTM ($) | 19.73 |
Price per Book TTM ($) | 25.72 |
PE Ratio (TTM) | 16.20 |
Book Value per Share ($) | 2.00 |
5 Year PE Range-35.4 |
Returns
7 Day Return | -7.01% | |
1 Month Return | -12.84% | |
3 Month Return | 20.83% | |
1 Year Return | 11.60% | |
3 Year Return | 180.31% | |
5 Year Return | 246.09% | |
YTD Return | 12.24% |
Risk
Analyst Estimates
Financial Health
Technicals
RSI (14 Day) | 38.67 |
14 Day SMA ($) | 49.09 |
14 Day EMA ($) | 48.09 |
Money Flow Index | 58.37 |
Average True Range | 1.89 |
50 Day SMA ($) | 47.09 |
200 Day SMA ($) | 40.00 |
ADX | 15.60 |
MACD | -0.05 |
Growth
Free Cash Flow QoQ Growth | -42.56% |
Free Cash Flow YoY Growth | 0.00% |
Revenue YoY Growth | 0.00% |
EPS QoQ Growth | -8.33% |
Revenue QoQ Growth | 14.98% |
EPS YoY Growth | 0.00% |
Profitability
Chart
News
Is Halozyme Therapeutics (HALO) A Worthy Long-Term Investment?
Yahoo Finance 2/28/2022
Halozyme: Steady Revenue Growth At A Reasonable Valuation
Seeking Alpha 2/26/2022
Halozyme (HALO) Q4 Earnings Top, Royalties Drive Revenues
Yahoo Finance 2/23/2022
Halozyme Therapeutics, Inc. 2021 Q4 - Results - Earnings Call Presentation
Seeking Alpha 2/22/2022
Halozyme Therapeutics, Inc.'s (HALO) CEO Helen Torley On Q4 2021 Results - Earnings Call Transcript
Seeking Alpha 2/22/2022
Halozyme Therapeutics (HALO) Q4 Earnings and Revenues Surpass Estimates
Yahoo Finance 2/22/2022
Halozyme Therapeutics Non-GAAP EPS of $0.42 beats by $0.01, revenue of $102M beats by $2.31M
Seeking Alpha 2/22/2022
HALOZYME REPORTS FOURTH QUARTER 2021 AND FULL YEAR RESULTS
Yahoo Finance 2/22/2022
Halozyme Therapeutics Q4 2021 Earnings Preview
Seeking Alpha 2/21/2022
Analysts Estimate Halozyme Therapeutics (HALO) to Report a Decline in Earnings: What to Look Out for
Yahoo Finance 2/15/2022
HALOZYME TO HOST FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS WEBCAST AND CONFERENCE CALL
Yahoo Finance 2/9/2022
The 8.2% return this week takes Halozyme Therapeutics' (NASDAQ:HALO) shareholders five-year gains to 189%
Yahoo Finance 2/3/2022
Halozyme appoints CFO from within ranks
Seeking Alpha 2/2/2022
Halozyme Appoints New Chief Financial Officer
Yahoo Finance 2/2/2022
United Asset Strategies, Inc. Buys Belpointe PREP LLC, ISHARES TRUST, The Walt Disney Co, Sells ...
Yahoo Finance 1/31/2022
New Strong Sell Stocks for January 13th
Yahoo Finance 1/13/2022
Halozyme Therapeutics (HALO) Presents At 40th Annual J.P. Morgan Virtual Healthcare Conference
Seeking Alpha 1/12/2022
Halozyme issues lower than expected guidance for 2022
Seeking Alpha 1/10/2022
HALOZYME PROVIDES 2022 FINANCIAL GUIDANCE AND OUTLOOK
Yahoo Finance 1/10/2022
Halozyme to Present Virtually at the 40th Annual J.P. Morgan Health Care Conference
Yahoo Finance 1/4/2022
Trend Analysis & Forecast
Read more on this trend analysis & forecast here - uptrenddowntrend.com
Trendlast: 46.195
Financials
HALO Income Statement
Annual
| Dec-12 | Dec-13 | Dec-14 | Dec-15 | Dec-16 | Dec-17 | Dec-18 | Dec-19 | Dec-20 | Dec-21 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 42 M | 55 M | 75 M | 135 M | 147 M | 317 M | 152 M | 196 M | 268 M | 443 M |
| Cost of sales | 15000 | 4 M | 20 M | 28 M | 18 M | 29 M | 11 M | 44 M | 39 M | 76 M |
| Gross operating profit | 41 M | 49 M | 53 M | 106 M | 113 M | 285 M | 142 M | 150 M | 224 M | 362 M |
| Selling Gen & administrative expense | 25 M | 32 M | 36 M | 40 M | 46 M | 54 M | 61 M | 77 M | 46 M | 50 M |
| Research & development expense | 70 M | 97 M | 80 M | 93 M | 151 M | 151 M | 150 M | 141 M | 34 M | 36 M |
| Operating income | -54 M | -80 M | -63 M | -27 M | -83 M | 81 M | -69 M | -68 M | 144 M | 276 M |
| floaterest income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| floaterest expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other income net | 73000 | 229000 | 242000 | 422000 | 1 M | 3 M | 8 M | 7 M | 5 M | -20 M |
| Pre-tax Income (EBT) | -54 M | -83 M | -68 M | -32 M | -102 M | 62 M | -80 M | -72 M | 129 M | 249 M |
| Income taxes | 0 | 0 | 0 | 0 | 1 M | -1 M | 537000 | -11000 | 217000 | -154 M |
| Net income from total operations | -54 M | -83 M | -68 M | -32 M | -103 M | 63 M | -80 M | -72 M | 129 M | 403 M |
| Minority floaterest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total net income | -54 M | -83 M | -68 M | -32 M | -103 M | 63 M | -80 M | -72 M | 129 M | 403 M |
| Preferred dividends | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net income available for common | -54 M | -83 M | -68 M | -32 M | -103 M | 63 M | -80 M | -72 M | 129 M | 403 M |
| Depreciation | 1 M | 2 M | 3 M | 2 M | 16 M | 2 M | -702000 | 2 M | 4 M | 5 M |
| Amortization | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating income before depreciation (EBITDA) | -52 M | -79 M | -61 M | -25 M | -79 M | 86 M | -59 M | -57 M | 153 M | 259 M |
| Total Income available for floaterest expense (EBIT) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Basic EPS total | -0.48 | -0.74 | -0.56 | -0.25 | -0.81 | 0.46 | -0.56 | -0.5 | 0.95 | 2.86 |
| Diluted EPS total | -0.48 | -0.74 | -0.56 | -0.25 | -0.81 | 0.45 | -0.56 | -0.5 | 0.91 | 2.74 |
Top MarketXLS Rank stocks
Call: 1-877-778-8358
I am so happy you are here. My name is Ankur and I am the founder/CEO of MarketXLS. Over the past four years, I have helped more than 2500 customers to implement their own investment research strategies and monitoring systems in Excel.
Get Access to 1 Billion Usable Market data points IN YOUR EXCEL SHEETS WITH EASY TO USE EXCEL FUNCTIONS
Get started today
Stand with Ukraine
As the situation in Ukraine escalates, many of us in MarketXLS are left with emotions too overwhelming to name. If you’d like to show your support, but aren’t sure how to, we want to help make it easier for you to act.
For any amount donated, we’ll extend your MarketXLS subscription for double of the donated amount. Please send proof of your payment to support@marketxls.com to avail the extention
From all of us at MarketXLS, thank you!